The Impact of Sildenafil on the Pulmonary Circulation in Healthy Trained and Untrained Humans

PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

July 1, 2021

Primary Completion Date

July 5, 2024

Study Completion Date

July 5, 2024

Conditions
Healthy
Interventions
DRUG

Sildenafil 50 mg

Sildenafil is a phosphodiesterase type-5 inhibitor, which augments/prolongs the naturally occurring nitric oxide mediated vasodilatory pathway. Sildenafil pill is over-encapsulated to be identical in appearance to the placebo intervention.

DRUG

Placebo

Medical-grade placebo pill, over-encapsulated to be identical in appearance to the sildenafil intervention.

Trial Locations (1)

T6G2R3

Clinical Physiology Laboratory, Edmonton

All Listed Sponsors
lead

University of Alberta

OTHER